Encorafenib, binimetinib and cetuximab in BRAF V600E-mutated advanced pancreatic adenocarcinoma

被引：0
|
作者：
Zaanan, A. [1 ]
Dabout, V. [1 ]
Garinet, S. [2 ]
Giraud, D. [3 ]
Perkins, G. [4 ]
Taieb, J. [1 ]
Gallois, C. [1 ]
机构：
[1] Paris Cite Univ, Georges Pompidou European Hosp, Dept Gastroenterol & Digest Oncol, SIRIC CARPEM, Paris, France
[2] Paris Cite Univ, Georges Pompidou European Hosp, Dept Biochem, SIR CARPEM, Paris, France
[3] Georges Pompidou European Hosp, Dept Pharm, Paris, France
[4] CHRU Pontchaillou, Dept Gastroenterol, Rennes, France
来源：
ESMO OPEN | 2024年 / 9卷 / 11期
关键词：
D O I：
10.1016/j.esmoop.2024.103975
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
    Sharma, Vinod
    Vanidassane, Ilavarasi
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 876 - 876
  • [2] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
    Roviello, Giandomenico
    D'Angelo, Alberto
    Petrioli, Roberto
    Roviello, Franco
    Cianchi, Fabio
    Nobili, Stefania
    Mini, Enrico
    Lavacchi, Daniele
    TRANSLATIONAL ONCOLOGY, 2020, 13 (09):
  • [3] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
    Kopetz, S.
    Grothey, A.
    Yaeger, R.
    Van Cutsem, E.
    Desai, J.
    Yoshino, T.
    Wasan, H.
    Ciardiello, F.
    Loupakis, F.
    Hong, Y. S.
    Steeghs, N.
    Guren, T. K.
    Arkenau, H. -T.
    Garcia-Alfonso, P.
    Pfeiffer, P.
    Orlov, S.
    Lonardi, S.
    Elez, E.
    Kim, T. -W.
    Schellens, J. H. M.
    Guo, C.
    Krishnan, A.
    Dekervel, J.
    Morris, V.
    Calvo Ferrandiz, A.
    Tarpgaard, L. S.
    Braun, M.
    Gollerkeri, A.
    Keir, C.
    Maharry, K.
    Pickard, M.
    Christy-Bittel, J.
    Anderson, L.
    Sandor, V.
    Tabernero, J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (17): : 1632 - 1643
  • [4] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer Reply
    Kopetz, Scott
    Grothey, Axel
    Tabernero, Josep
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 877 - 878
  • [5] Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E-mutated colorectal cancer
    Stammler, Romain
    Gallois, Claire
    Taieb, Julien
    Duong, Jean-Paul
    Karras, Alexandre
    Thervet, Eric
    Lazareth, Helene
    EUROPEAN JOURNAL OF CANCER, 2021, 147 : 60 - 62
  • [6] Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA
    Li, Shuosha
    Hu, Huabin
    Ding, Dong
    Zhu, Youwen
    Huang, Jin
    ADVANCES IN THERAPY, 2021, 38 (03) : 1650 - 1659
  • [7] Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA
    Shuosha Li
    Huabin Hu
    Dong Ding
    Youwen Zhu
    Jin Huang
    Advances in Therapy, 2021, 38 : 1650 - 1659
  • [8] Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: an early post-marketing phase vigilance study
    Sakata, Hidenori
    Murase, Maki
    Kato, Takeshi
    Yamaguchi, Kensei
    Sugihara, Kenichi
    Suzuki, Shigenobu
    Yoshino, Takayuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (01) : 139 - 144
  • [9] Clinical and Radiographic Response of Leptomeningeal and Brain Metastases to Encorafenib and Binimetinib in a Patient With BRAF V600E-Mutated Lung Adenocarcinoma
    McLoughlin, Erin M.
    Fadul, Camilo E.
    Patel, Sohil H.
    Hall, Richard D.
    Gentzler, Ryan D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (12) : E269 - E271
  • [10] TRESBIEN (OGSG 2101): Encorafenib, binimetinib and cetuximab for early relapse stage II/III BRAF V600E-mutated CRC
    Boku, S.
    Satake, H.
    Ohta, T.
    Mitani, S.
    Kawakami, K.
    Matsumoto, T.
    Yamazaki, E.
    Hasegawa, H.
    Ikoma, T.
    Uemura, M.
    Yamaguchi, T.
    Ishizuka, Y.
    Kurokawa, Y.
    Sakai, D.
    Kawakami, H.
    Shimokawa, T.
    Tsujinaka, T.
    Kato, T.
    Satoh, T.
    Kagawa, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S735 - S736
12345